PMC:7441788 / 19229-19720 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T110","span":{"begin":307,"end":309},"obj":"Body_part"}],"attributes":[{"id":"A110","pred":"fma_id","subj":"T110","obj":"http://purl.org/sig/ont/fma/fma86578"}],"text":"Yu et al [56]. Retrospective study HCQ group: n = 48; no-HCQ group: n = 502 HCQ (200 mg/2 times/day, for 7 to 10 days) The fatalities of HCQ group was significantly lower than no-HCQ group. HCQ treatment was related to significantly reduced mortality in critically ill COVID-19 patients and greatly lowered IL-6 level. Mortality was used as a measure of outcome and the study included critically ill patients. Retrospective design of the study and the number of HCQ group patients was small."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T103","span":{"begin":269,"end":277},"obj":"Disease"}],"attributes":[{"id":"A103","pred":"mondo_id","subj":"T103","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Yu et al [56]. Retrospective study HCQ group: n = 48; no-HCQ group: n = 502 HCQ (200 mg/2 times/day, for 7 to 10 days) The fatalities of HCQ group was significantly lower than no-HCQ group. HCQ treatment was related to significantly reduced mortality in critically ill COVID-19 patients and greatly lowered IL-6 level. Mortality was used as a measure of outcome and the study included critically ill patients. Retrospective design of the study and the number of HCQ group patients was small."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T183","span":{"begin":50,"end":52},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T184","span":{"begin":341,"end":342},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Yu et al [56]. Retrospective study HCQ group: n = 48; no-HCQ group: n = 502 HCQ (200 mg/2 times/day, for 7 to 10 days) The fatalities of HCQ group was significantly lower than no-HCQ group. HCQ treatment was related to significantly reduced mortality in critically ill COVID-19 patients and greatly lowered IL-6 level. Mortality was used as a measure of outcome and the study included critically ill patients. Retrospective design of the study and the number of HCQ group patients was small."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T233","span":{"begin":39,"end":44},"obj":"Chemical"},{"id":"T234","span":{"begin":61,"end":66},"obj":"Chemical"},{"id":"T235","span":{"begin":141,"end":146},"obj":"Chemical"},{"id":"T236","span":{"begin":183,"end":188},"obj":"Chemical"},{"id":"T237","span":{"begin":307,"end":309},"obj":"Chemical"},{"id":"T239","span":{"begin":466,"end":471},"obj":"Chemical"}],"attributes":[{"id":"A233","pred":"chebi_id","subj":"T233","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A234","pred":"chebi_id","subj":"T234","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A235","pred":"chebi_id","subj":"T235","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A236","pred":"chebi_id","subj":"T236","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A237","pred":"chebi_id","subj":"T237","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A238","pred":"chebi_id","subj":"T237","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A239","pred":"chebi_id","subj":"T239","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"}],"text":"Yu et al [56]. Retrospective study HCQ group: n = 48; no-HCQ group: n = 502 HCQ (200 mg/2 times/day, for 7 to 10 days) The fatalities of HCQ group was significantly lower than no-HCQ group. HCQ treatment was related to significantly reduced mortality in critically ill COVID-19 patients and greatly lowered IL-6 level. Mortality was used as a measure of outcome and the study included critically ill patients. Retrospective design of the study and the number of HCQ group patients was small."}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T105","span":{"begin":269,"end":277},"obj":"Species"}],"attributes":[{"id":"A105","pred":"ncbi_taxonomy_id","subj":"T105","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"Yu et al [56]. Retrospective study HCQ group: n = 48; no-HCQ group: n = 502 HCQ (200 mg/2 times/day, for 7 to 10 days) The fatalities of HCQ group was significantly lower than no-HCQ group. HCQ treatment was related to significantly reduced mortality in critically ill COVID-19 patients and greatly lowered IL-6 level. Mortality was used as a measure of outcome and the study included critically ill patients. Retrospective design of the study and the number of HCQ group patients was small."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T143","span":{"begin":0,"end":14},"obj":"Sentence"},{"id":"T144","span":{"begin":15,"end":189},"obj":"Sentence"},{"id":"T145","span":{"begin":190,"end":318},"obj":"Sentence"},{"id":"T146","span":{"begin":319,"end":409},"obj":"Sentence"},{"id":"T147","span":{"begin":410,"end":491},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Yu et al [56]. Retrospective study HCQ group: n = 48; no-HCQ group: n = 502 HCQ (200 mg/2 times/day, for 7 to 10 days) The fatalities of HCQ group was significantly lower than no-HCQ group. HCQ treatment was related to significantly reduced mortality in critically ill COVID-19 patients and greatly lowered IL-6 level. Mortality was used as a measure of outcome and the study included critically ill patients. Retrospective design of the study and the number of HCQ group patients was small."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"641","span":{"begin":307,"end":311},"obj":"Gene"},{"id":"647","span":{"begin":278,"end":286},"obj":"Species"},{"id":"648","span":{"begin":400,"end":408},"obj":"Species"},{"id":"649","span":{"begin":472,"end":480},"obj":"Species"},{"id":"680","span":{"begin":35,"end":38},"obj":"Chemical"},{"id":"681","span":{"begin":57,"end":60},"obj":"Chemical"},{"id":"682","span":{"begin":76,"end":79},"obj":"Chemical"},{"id":"683","span":{"begin":137,"end":140},"obj":"Chemical"},{"id":"684","span":{"begin":179,"end":182},"obj":"Chemical"},{"id":"685","span":{"begin":190,"end":193},"obj":"Chemical"},{"id":"713","span":{"begin":241,"end":250},"obj":"Disease"},{"id":"714","span":{"begin":254,"end":268},"obj":"Disease"},{"id":"715","span":{"begin":269,"end":277},"obj":"Disease"},{"id":"716","span":{"begin":319,"end":328},"obj":"Disease"},{"id":"717","span":{"begin":385,"end":399},"obj":"Disease"}],"attributes":[{"id":"A717","pred":"pubann:denotes","subj":"717","obj":"MESH:D016638"},{"id":"A715","pred":"pubann:denotes","subj":"715","obj":"MESH:C000657245"},{"id":"A680","pred":"pubann:denotes","subj":"680","obj":"MESH:D006886"},{"id":"A647","pred":"pubann:denotes","subj":"647","obj":"Tax:9606"},{"id":"A714","pred":"pubann:denotes","subj":"714","obj":"MESH:D016638"},{"id":"A641","pred":"pubann:denotes","subj":"641","obj":"Gene:3569"},{"id":"A685","pred":"pubann:denotes","subj":"685","obj":"MESH:D006886"},{"id":"A682","pred":"pubann:denotes","subj":"682","obj":"MESH:D006886"},{"id":"A716","pred":"pubann:denotes","subj":"716","obj":"MESH:D003643"},{"id":"A649","pred":"pubann:denotes","subj":"649","obj":"Tax:9606"},{"id":"A681","pred":"pubann:denotes","subj":"681","obj":"MESH:D006886"},{"id":"A683","pred":"pubann:denotes","subj":"683","obj":"MESH:D006886"},{"id":"A684","pred":"pubann:denotes","subj":"684","obj":"MESH:D006886"},{"id":"A713","pred":"pubann:denotes","subj":"713","obj":"MESH:D003643"},{"id":"A648","pred":"pubann:denotes","subj":"648","obj":"Tax:9606"}],"text":"Yu et al [56]. Retrospective study HCQ group: n = 48; no-HCQ group: n = 502 HCQ (200 mg/2 times/day, for 7 to 10 days) The fatalities of HCQ group was significantly lower than no-HCQ group. HCQ treatment was related to significantly reduced mortality in critically ill COVID-19 patients and greatly lowered IL-6 level. Mortality was used as a measure of outcome and the study included critically ill patients. Retrospective design of the study and the number of HCQ group patients was small."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T1214","span":{"begin":307,"end":311},"obj":"Protein"}],"attributes":[{"id":"A1214","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q9XT80"},{"id":"A1215","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q9UCU4"},{"id":"A1216","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q9UCU3"},{"id":"A1217","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q9UCU2"},{"id":"A1218","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q9MZR1"},{"id":"A1219","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q9MYZ7"},{"id":"A1220","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q95KN6"},{"id":"A1221","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q95181"},{"id":"A1222","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q90YI0"},{"id":"A1223","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q8MKH0"},{"id":"A1224","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q8BN26"},{"id":"A1225","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q865X6"},{"id":"A1226","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q865W7"},{"id":"A1227","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q6V919"},{"id":"A1228","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q6L6X6"},{"id":"A1229","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q5I6E3"},{"id":"A1230","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q3UCQ0"},{"id":"A1231","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q2MH06"},{"id":"A1232","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q28819"},{"id":"A1233","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q28747"},{"id":"A1234","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q28319"},{"id":"A1235","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q25BC2"},{"id":"A1236","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q0PW36"},{"id":"A1237","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q0GGL7"},{"id":"A1238","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/Q08DT2"},{"id":"A1239","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/P79341"},{"id":"A1240","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/P51494"},{"id":"A1241","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/P46650"},{"id":"A1242","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/P41693"},{"id":"A1243","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/P41683"},{"id":"A1244","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/P41323"},{"id":"A1245","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/P29455"},{"id":"A1246","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/P26893"},{"id":"A1247","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/P26892"},{"id":"A1248","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/P20607"},{"id":"A1249","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/P08505"},{"id":"A1250","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/P05231"},{"id":"A1251","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/O46568"},{"id":"A1252","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/O35736"},{"id":"A1253","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/O19007"},{"id":"A1254","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/B6CKP4"},{"id":"A1255","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/A9QWQ9"},{"id":"A1256","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/A3FBE9"},{"id":"A1257","pred":"uniprot_id","subj":"T1214","obj":"https://www.uniprot.org/uniprot/A0S0B0"}],"text":"Yu et al [56]. Retrospective study HCQ group: n = 48; no-HCQ group: n = 502 HCQ (200 mg/2 times/day, for 7 to 10 days) The fatalities of HCQ group was significantly lower than no-HCQ group. HCQ treatment was related to significantly reduced mortality in critically ill COVID-19 patients and greatly lowered IL-6 level. Mortality was used as a measure of outcome and the study included critically ill patients. Retrospective design of the study and the number of HCQ group patients was small."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T109","span":{"begin":307,"end":309},"obj":"Body_part"}],"attributes":[{"id":"A109","pred":"fma_id","subj":"T109","obj":"http://purl.org/sig/ont/fma/fma86578"}],"text":"Yu et al [56]. Retrospective study HCQ group: n = 48; no-HCQ group: n = 502 HCQ (200 mg/2 times/day, for 7 to 10 days) The fatalities of HCQ group was significantly lower than no-HCQ group. HCQ treatment was related to significantly reduced mortality in critically ill COVID-19 patients and greatly lowered IL-6 level. Mortality was used as a measure of outcome and the study included critically ill patients. Retrospective design of the study and the number of HCQ group patients was small."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T96","span":{"begin":269,"end":277},"obj":"Disease"}],"attributes":[{"id":"A96","pred":"mondo_id","subj":"T96","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Yu et al [56]. Retrospective study HCQ group: n = 48; no-HCQ group: n = 502 HCQ (200 mg/2 times/day, for 7 to 10 days) The fatalities of HCQ group was significantly lower than no-HCQ group. HCQ treatment was related to significantly reduced mortality in critically ill COVID-19 patients and greatly lowered IL-6 level. Mortality was used as a measure of outcome and the study included critically ill patients. Retrospective design of the study and the number of HCQ group patients was small."}

{"project":"LitCovid-PubTator","denotations":[{"id":"641","span":{"begin":307,"end":311},"obj":"Gene"},{"id":"647","span":{"begin":278,"end":286},"obj":"Species"},{"id":"648","span":{"begin":400,"end":408},"obj":"Species"},{"id":"649","span":{"begin":472,"end":480},"obj":"Species"},{"id":"680","span":{"begin":35,"end":38},"obj":"Chemical"},{"id":"681","span":{"begin":57,"end":60},"obj":"Chemical"},{"id":"682","span":{"begin":76,"end":79},"obj":"Chemical"},{"id":"683","span":{"begin":137,"end":140},"obj":"Chemical"},{"id":"684","span":{"begin":179,"end":182},"obj":"Chemical"},{"id":"685","span":{"begin":190,"end":193},"obj":"Chemical"},{"id":"713","span":{"begin":241,"end":250},"obj":"Disease"},{"id":"714","span":{"begin":254,"end":268},"obj":"Disease"},{"id":"715","span":{"begin":269,"end":277},"obj":"Disease"},{"id":"716","span":{"begin":319,"end":328},"obj":"Disease"},{"id":"717","span":{"begin":385,"end":399},"obj":"Disease"}],"attributes":[{"id":"A641","pred":"tao:has_database_id","subj":"641","obj":"Gene:3569"},{"id":"A647","pred":"tao:has_database_id","subj":"647","obj":"Tax:9606"},{"id":"A648","pred":"tao:has_database_id","subj":"648","obj":"Tax:9606"},{"id":"A649","pred":"tao:has_database_id","subj":"649","obj":"Tax:9606"},{"id":"A680","pred":"tao:has_database_id","subj":"680","obj":"MESH:D006886"},{"id":"A681","pred":"tao:has_database_id","subj":"681","obj":"MESH:D006886"},{"id":"A682","pred":"tao:has_database_id","subj":"682","obj":"MESH:D006886"},{"id":"A683","pred":"tao:has_database_id","subj":"683","obj":"MESH:D006886"},{"id":"A684","pred":"tao:has_database_id","subj":"684","obj":"MESH:D006886"},{"id":"A685","pred":"tao:has_database_id","subj":"685","obj":"MESH:D006886"},{"id":"A713","pred":"tao:has_database_id","subj":"713","obj":"MESH:D003643"},{"id":"A714","pred":"tao:has_database_id","subj":"714","obj":"MESH:D016638"},{"id":"A715","pred":"tao:has_database_id","subj":"715","obj":"MESH:C000657245"},{"id":"A716","pred":"tao:has_database_id","subj":"716","obj":"MESH:D003643"},{"id":"A717","pred":"tao:has_database_id","subj":"717","obj":"MESH:D016638"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Yu et al [56]. Retrospective study HCQ group: n = 48; no-HCQ group: n = 502 HCQ (200 mg/2 times/day, for 7 to 10 days) The fatalities of HCQ group was significantly lower than no-HCQ group. HCQ treatment was related to significantly reduced mortality in critically ill COVID-19 patients and greatly lowered IL-6 level. Mortality was used as a measure of outcome and the study included critically ill patients. Retrospective design of the study and the number of HCQ group patients was small."}

{"project":"LitCovid-sentences","denotations":[{"id":"T143","span":{"begin":0,"end":14},"obj":"Sentence"},{"id":"T144","span":{"begin":15,"end":189},"obj":"Sentence"},{"id":"T145","span":{"begin":190,"end":318},"obj":"Sentence"},{"id":"T146","span":{"begin":319,"end":409},"obj":"Sentence"},{"id":"T147","span":{"begin":410,"end":491},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Yu et al [56]. Retrospective study HCQ group: n = 48; no-HCQ group: n = 502 HCQ (200 mg/2 times/day, for 7 to 10 days) The fatalities of HCQ group was significantly lower than no-HCQ group. HCQ treatment was related to significantly reduced mortality in critically ill COVID-19 patients and greatly lowered IL-6 level. Mortality was used as a measure of outcome and the study included critically ill patients. Retrospective design of the study and the number of HCQ group patients was small."}